Post‐ harvest consideration factors for microRNA research in cellular, tissue, serum and plasma samples

Chiang, Vic Shao-Chih

doi:10.1002/cbin.10346

Cited by 3 publications

(3 citation statements)

References 51 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41 In this study, a special microRNA adsorption column was used for RNA extraction. Serum microRNAs are little in content and short in length.…”

Section: Discussionmentioning

confidence: 99%

“…Conventional Trizol extraction method may cause excessive loss of serum microRNAs. 41 In this study, a special microRNA adsorption column was used for RNA extraction. There are no standard endogenous controls for circulating microRNA.…”

Section: Discussionmentioning

confidence: 99%

“…Serum microRNAs are little in content and short in length. Conventional Trizol extraction method may cause excessive loss of serum microRNAs . In this study, a special microRNA adsorption column was used for RNA extraction.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Peripheral blood circulating microRNA‐4636/−143 for the prognosis of cervical cancer

Yin

Yang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cervical cancer is the third leading cause of female death in the world. Serum microRNAs (miRNAs) are currently considered to be valuable as noninvasive cancer biomarkers, but their role in the prognosis of cervical cancer has not been elucidated. We aimed to find serum miRNAs that can be used as prognostic factors for cervical cancer. A traumatic pathological biopsy is the only reliable method for determining the severity of cervical cancer currently. Thus, noninvasive diagnostic markers are needed. The serological expression of candidate miRNAs were measured in 90 participants, including 60 patients with cervical cancer and 50 patients with cervical intraepithelial neoplasia. Two patients with cervical cancer were excluded from the study because of lack of data. miRNAs were evaluated by quantitative reverse transcription polymerase chain reaction. miR‐143/−4636 appeared specific for cervical cancer compared with cervical intraepithelial neoplasia (P < .001). The classification performance of validated miRNAs for cervical cancer [Area under the receiver operating characteristic curve (AUC) = 0.942] was better than that reached by squamous cell carcinoma antigen (SCC‐Ag; AUC = 0.727). Poor‐differentiation group has lower miR‐143/−4636 levels in serum (P < .05). miR‐4636 level was correlated gross tumor volume and the depth of invasion (P < .0001). In our study, we found a combination of miR‐143 and miR‐4636 that is independently and strongly associated with cervical cancer prognosis and can be used as a clinically prognostic factor.

show abstract

“…41 In this study, a special microRNA adsorption column was used for RNA extraction. Serum microRNAs are little in content and short in length.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Peripheral blood circulating microRNA‐4636/−143 for the prognosis of cervical cancer

Yin

Yang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

Circulating microRNA 216 as a Marker for the Early Identification of Severe Acute Pancreatitis

Zhang

Deng

Chen

et al. 2017

The American Journal of the Medical Sciences

View full text Add to dashboard Cite

Advancing the use of noncoding RNA in regulatory toxicology: Report of an ECETOC workshop

Aigner¹,

Buesen²,

Gant³

et al. 2016

Regulatory Toxicology and Pharmacology

View full text Add to dashboard Cite

The European Centre for the Ecotoxicology and Toxicology of Chemicals (ECETOC) organised a workshop to discuss the state-of-the-art research on noncoding RNAs (ncRNAs) as biomarkers in regulatory toxicology and as analytical and therapeutic agents. There was agreement that the abundance of data obtained from ncRNA expression profiling requires careful evaluation to determine the utility of specific ncRNAs for regulatory toxicology. To advance the use of ncRNA in regulatory toxicology, the following research priorities were identified: (1) Conduct comprehensive literature reviews to identify candidate ncRNAs for further assessment as potential biomarkers of toxicity and areas of toxicology where ncRNA expression profiling can address prevailing scientific deficiencies.(2) Develop consensus on how to conduct and report ncRNA expression profiling in a toxicological context to support applicability for regulatory decision-making. (3) Conduct experimental projects to evaluate the toxicological relevance of the expression profiles of selected ncRNAs. As necessary, retrospective analyses (e.g. from surplus samples from control groups from regulatory studies) can be supplemented with new (90-day) rat oral toxicity studies. These projects should aim at establishing physiological ncRNA expression profiles including the biological variability of healthy individuals. To substantiate the relevance of key ncRNAs for cell homeostasis or pathogenesis, molecular events should be linked with substance-induced apical effects in a dose-dependent manner. Applying a holistic approach, knowledge on ncRNAs, and relevant information from 'omics and epigenetics technologies, should be integrated into adverse outcome pathways to improve the understanding of the functional roles of ncRNAs within a regulatory context.

show abstract

Post‐ harvest consideration factors for microRNA research in cellular, tissue, serum and plasma samples

Cited by 3 publications

References 51 publications

Peripheral blood circulating microRNA‐4636/−143 for the prognosis of cervical cancer

Peripheral blood circulating microRNA‐4636/−143 for the prognosis of cervical cancer

Circulating microRNA 216 as a Marker for the Early Identification of Severe Acute Pancreatitis

Advancing the use of noncoding RNA in regulatory toxicology: Report of an ECETOC workshop

Contact Info

Product

Resources

About